0000899243-21-039941.txt : 20211012
0000899243-21-039941.hdr.sgml : 20211012
20211012193609
ACCESSION NUMBER: 0000899243-21-039941
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211008
FILED AS OF DATE: 20211012
DATE AS OF CHANGE: 20211012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ehrlich Christopher B
CENTRAL INDEX KEY: 0001293973
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40877
FILM NUMBER: 211319797
MAIL ADDRESS:
STREET 1: 499 ILLINOIS STREET, SUITE 200
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PHOENIX BIOTECH ACQUISITION CORP.
CENTRAL INDEX KEY: 0001870404
STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770]
IRS NUMBER: 871088814
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2001 MARKET STREET
STREET 2: SUITE 3400
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
BUSINESS PHONE: 2157319450
MAIL ADDRESS:
STREET 1: 2001 MARKET STREET
STREET 2: SUITE 3400
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-10-08
0
0001870404
PHOENIX BIOTECH ACQUISITION CORP.
PBAX
0001293973
Ehrlich Christopher B
2201 BROADWAY, SUITE 705
OAKLAND
CA
94612
1
1
1
0
CEO and Secretary
Class A common stock
2021-10-08
4
J
0
36733
10.00
A
699996
I
By Phoenix Biotech Sponsor, LLC
Class B Common Stock
2021-10-08
4
J
0
82875
D
Class A Common Stock
82875
4596250
I
By Phoenix Biotech Sponsor, LLC
Warrants
11.50
2021-10-08
4
J
0
18366
0.00
A
Class A Common Stock
18366
349998
I
By Phoenix Biotech Sponsor, LLC
Acquisition by the issuer's sponsor, Phoenix Biotech Sponsor, LLC (the "Sponsor") in connection with the partial exercise of the underwriters' over-allotment option.
These shares underlie the same number of units of the issuer held by the reporting person.
The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date.
Forfeiture and cancellation of shares of Class B common stock for no consideration because the underwriters' over-allotment option was not exercised in full.
These securities are held directly by the Sponsor, which managed by the reporting person. As a result, all of the securities may be deemed to be beneficially held by the reporting person. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose.
The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering.
The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation.
/s/ Chris Ehrlich
2021-10-12